Search alternatives:
significantly point » significantly onto (Expand Search), significantly poorer (Expand Search), significantly lower (Expand Search)
point decrease » point increase (Expand Search)
teer decrease » greater decrease (Expand Search)
significantly point » significantly onto (Expand Search), significantly poorer (Expand Search), significantly lower (Expand Search)
point decrease » point increase (Expand Search)
teer decrease » greater decrease (Expand Search)
-
1
-
2
-
3
-
4
-
5
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
Published 2024“…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns = not significant.…”
-
6
-
7
-
8
MiR-129-5p levels were decreased in mouse depression models.
Published 2025“…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. The gray points represent miRNAs with no significant change (p < 0.05, false discovery rate (FDR) q < 0.05), while red and blue points indicate upregulated and downregulated miRNAs (p < 0.05, FDR q < 0.05), respectively. …”
-
9
-
10
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
Published 2025“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”
-
11
-
12
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
13
-
14
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
15
-
16
-
17
-
18
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
19
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
20
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: